Skip to content
OpenCapital
Get started
CG Oncology logo

CG Oncology (CGON) Q1 2026 Earnings

CGON·Reported May 8, 2026·Before market open

CG Oncology reported Q1 2026 revenue of $1.1M (+1982.7% YoY), beat analyst consensus of $453.0K by $630.0K. Diluted EPS came in at $-0.71 (-57.8% YoY), missed the $-0.58 consensus by $0.13.

Revenue
$1.1Mbeat by $630.0K
Consensus: $453.0K
Diluted EPS
$-0.71missed by $0.13
Consensus: $-0.58
SEC

SEC Filings

Earnings release8-K · 0001193125-26-213440
Quarterly report10-Q · 0001193125-26-214669

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about CG Oncology's Q1 2026 earnings report.

CG Oncology (CGON) reported Q1 2026 earnings on May 8, 2026 before market open.

CG Oncology reported revenue of $1.1M and diluted EPS of $-0.71 for Q1 2026.

Revenue beat the consensus estimate of $453.0K by $630.0K. EPS missed the consensus estimate of $-0.58 by $0.13.

Compared to the same quarter a year prior, revenue grew 1982.7% from $52.0K a year earlier and diluted EPS declined 57.8% from $-0.45.

You can read the 8-K earnings release (0001193125-26-213440) and the 10-Q periodic report (0001193125-26-214669) directly on SEC EDGAR. The filing index links above go to sec.gov.